Metabolic and vascular effect of progestins in post-menopausal women: Implications for cardioprotection

Maturitas

Volumn 46, Issue SUPPL. 1, 2003, Pages 17-29

  Rosano, Giuseppe M C ^a   Vitale, Cristiana ^a   Silvestri, Antonello ^a   Fini, Massimo ^a  

^a IRCCS San Raffael   (Italy)

Author keywords

Cardioprotection; Diabetes; Endothelial function; Hormone replacement therapy; Metabolic and vascular effect; Progestins

Indexed keywords

ALGESTONE; ANDROGEN; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYPROTERONE; DIURETIC AGENT; DROSPIRENONE; DYDROGESTERONE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; GESTAGEN; GESTODENE; HYDROXYPROGESTERONE; INSULIN; LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; NANDROLONE DERIVATIVE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; PROGESTERONE; PROGESTERONE RECEPTOR; SIMVASTATIN; TIBOLONE;

ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL; BLOOD VESSEL REACTIVITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FIBRINOLYSIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMOSTASIS; HORMONAL THERAPY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN RESPONSE; LIPID METABOLISM; MENOPAUSE; META ANALYSIS; METABOLISM; NONHUMAN; POSTMENOPAUSE; REVIEW; RISK FACTOR; SIDE EFFECT; SODIUM METABOLISM; SYNDROME X; THORAX PAIN;

EID: 0345167225     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.09.015     Document Type: Article

References (57)

1. Bush T.L., Barret-Connor E., Cowan L.D. Cardiovascular mortality and noncontraceptive use of estrogen in women:results from Lipid Research Clinics Program Follow up Study. Circulation. 75:1987;1102-1109.
2. Kannel W.B. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am. Heart J. 114:1987;413-419.
3. American Heart Association. 2002 Heart and stroke statistical update. Dallas (TX): American Heart Association; 2001.
4. Grodstein F., Stampfer M.J. The epidemiology of coronary heart disease and estrogen replacement therapy in post-menopausal women. Prog. Cardiovasc. Dis. 88:1995;199-210.
5. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B.et al. Post-menopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335:1996;453-461.
6. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B.et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA. 280:1998;605-613.
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
8. Grady D., Rubin S.M., Petitti D.B., Fox C.S., Black D., Ettinger B.et al. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann. Intern. Med. 117:1992;1016-1037.
9. Ettinger B., Friedman G.D., Bush T., Quesenberry C.P. Reduced mortality associated with long-term post-menopausal estrogen therapy. Obstet. Gynecol. 87:1996;6-12.
10. Henderson B.E., Paganini-Hill A., Ross R.K. Decreased mortality in users of estrogen replacement therapy. Arch. Intern. Med. 151:1991;75-78.
11. Rosano G.M.C., Panina G. Oestrogens and the heart. Therapie. 54:1999;381-385.
12. Rosano G.M.C., Leonardo F., Sarrel P.M., Beale C., De Luca F., Collins P. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet. 347:1996;786-788.
13. Gray R.S., Fabsitz R.R., Cowan L.D., Lee E.T., Howard B.V., Savage P.J. Risk factor clustering in the insulin resistance syndrome: the Strong Heart Study. Am. J. Epidemiol. 148:1998;869-878.
14. Diabetes Statistics. National diabetes information Clearinghouse. NIH publication 99-3926. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 1999.
15. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847.
16. Brezinka V., Padmos I. Coronary heart disease risk factors in women. Eur. Heart J. 15:1994;1571-1584.
17. Geiss LS, Herman WH, Smith PJ, National Diabetes Data Group. Diabetes in America. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995. p. 233-57.
18. Reaven GM. Insulin resistance and its consequences: non-insulin- dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes mellitus: a fundamental and clinical text. Philadelphia (PA): Lippincott-Raven Publishers; 1996. p. 509-19.
19. The Post-menopausal Estrogen/Progestin Intervention Trial Writing Group. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. JAMA 1995;273:199-208.
20. Sporrong T.et al. Haemostatic changes during continuous oestradiol-progestogen treatment of post-menopausal women. Br. J. Obstet. Gynecol. 97:1990;939-944.
21. Notelowitz M., Johnston M., Smith S., Kitchens C. Metabolic and hormonal effects of 25 mg and 50 mg 17β estradiol implants in surgically menopausal women. Obstet. Gynecol. 70:1987;749-754.
22. Godsland I.F., Gangar K.F., Walton C., Cust M.P., Whitehead M.I., Wynn V.et al. Insulin resistance, secretion, and elimination in post-menopausal women receiving oral or transdermal hormone replacement therapy. Metabolism. 42:1993;846-853.
23. Godsland I.F. The influence of female sex steroids on glucose metabolism and insulin action. J. Intern. Med. 240(Suppl 738):1996;1-60.
24. Crook D., Godsland I.F., Hull J., Stevenson J. Hormone replacement therapy with dydrogesterone and 17beta estradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br. J. Obstet. Gynecol. 104:1997;298-304.
25. Gelfand M.M., Fugere P., Bissonnette F., Wiita B., Yang H.M., Lorrain J.et al. Conjugated equine estrogens combined with sequential dydrogesterone or medroxyprogeterone acetate in post-menopausal women: effects on lipoproteins, glucose tolerance, endometrial histology and bleeding. Menopause. 4:1997;10-18.
26. Mosnier-Pudar H., Faguer B., Guyenne T.T., Tchobroutski B. Effect de la substitution par 17 beta estradiol percutané et progestérone orale sur la pression artérielle et les paramètres métaboliques chez des patientes ménopausées diabétiques non insulinodépendantes. Arch. Mal. Coeur. 84:1991;1111-1115.
27. Castelli W.P. Cardiovascular disease in women. Am. J. Obstet. Gynecol. 158:1988;1553-1560.
28. Darling G.M., Johns J.A., McCloud P.I., Davis S.R. Estrogen and progestin compared with simvastatin for hypercholesterolemia in post-menopausal women. N. Engl. J. Med. 337:1997;595-601.
29. Sbarouni E., Kyriakides Z.S., Kremastinos D.T. The effect of hormone replacement therapy alone or in combination with simvastatin on plasma lipids of hypercholesterolemic post-menopausal women with coronary artery disease. J. Am. Coll. Cardiol. 32:1998;1244-1250.
30. Davidson M., Testolin L.M., Maki K.C., von Duvillard S., Drennan K. A comparison of estrogen replacement, pravastatin and combined treatment for the management of hypercholesterolemia in post-menopausal women. Arch. Intern. Med. 157:1997;1186-1192.
31. Herrington D.M., Werbel B.L., Riley W.A., Pusser B.E., Morgan T.M. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in post-menopausal women with coronary artery disease. J. Am. Coll. Cardiol. 33(7):1999;2030-2037.
32. Gebara O.C.E., Mittlemann M.A., Sutherland P.et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 91:1995;1952-1958.
33. Koh K.K., Mincemoyer R., Bui M.N.et al. Effects of hormone-replacement therapy on fibrinolysis in post-menopausal women. N. Engl. J. Med. 336:1997;683-690.
34. Sporrong T.et al. Haemostatic changes during continuous oestradiol-progestogen treatment of post-menopausal women. Br. J. Obstet. Gynecol. 97:1990;939-944.
35. Hanggi W., Lippuner K., Riesen W., Jaeger P., Birkhauser M.H. Long-term influence of different post-menopausal hormone replacement regimens on serum lipids and lipoprotein (a): a randomized study. Br. J. Obstet. Gynaecol. 104(6):1997;708-717.
36. Mijatovic V., Kenemans P., Netelenbos J.C., Peters-Muller E.R., van Kamp G.J., Voetberg G.A.et al. Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein (a) concentrations in healthy post-menopausal women. J. Clin. Endocrinol. Metab. 82(11):1997;3543-3547.
37. Adams M.R., Kaplan J.R., Manuck S.B.et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis. 10:1990;1051-1057.
38. Adams MR, Register TC, Wagner JD, Williams JK, Effects of estrogens and progestins on the pathogenesis of atherosclerosis in nonhuman primate. In: Forte TM, editor. Hormonal, metabolic and cellular influences on cardiovascular disease in women. New York: Futura Publishing Company, Inc.; 1997. p. 39-53.
39. Clarkson TB, Kaplan JR, Wagner JD, Williams JK, Adams MR. Lessons from animal models. In: Douglas PS, editor. Cardiovascular health and disease in women. 2nd ed. Philadelphia: WB Saunders; 2002. p. 231-56.
40. Herrington D.M., Reboussin D.M., Brosnihan K.B.et al. Effect of estrogen replacement on the progression of coronary atherosclerosis. N. Engl. J. Med. 343(8):2000;522-529.
41. Hodis H.N., Mack W.J., Lobo R.A., Shoupe D., Sevanian A., Mahrer P.R.et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 135:2001;939-953.
42. Angerer P., Stork S., Kothny W., Schmitt P., von Schacky C. Effect of oral post-menopausal hormone replacement on progression of atherosclerosis. A randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 21:2001;262-268.
43. Le Gal G., Gourlet V., Hogrel P., Plu-Bureau G., Touboul P.J., Scarabin P.Y. Hormone replacement therapy is associated with lower occurrence of carotid atherosclerotic plaque but not with intima-media thickness progression among post-menopausal women. Atherosclerosis. 166:2003;163-170.
44. Williams J.K., Honore E.K., Washburn S.A., Clarkson T.B. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J. Am. Coll. Cardiol. 24:1994;1757-1761.
45. Miller V.M., Vanoutte P.M. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am. J. Phisiol. 261:1991;R1022-R1027.
46. Gambacciani M., Monteleone P., Vitale C., Silvestri A., Fini M., Genazzani A.R.et al. Dydrogesterone does not reverse the effects of estradiol on endothelium dependent vasodilation in post-menopausal women: a randomized clinical trial. Maturitas. 43(2):2002;117-121.
47. Vitale C., Fini M., Leonardo F., Rossini P., Cerquetani E., Onorati D.et al. Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of post-menopausal women at increased risk for cardiovascular disease. Maturitas. 40(3):2001;239-245.
48. Rosano G.M.C., Mercuro G., Vitale C., Rossini P., Galetta P., Fini M. How progestins influence the cardiovascular effect of hormone replacement therapy. Gynecol. Endocrinol. 15(6):2001;9-17.
49. Penotti M., Nencioni T., Gabrielli L.et al. Blood flow variations in internal carotid and middle cerebral arteries induced by post-menopausal hormone replacement therapy. Am. J. Obstet. Gynecol. 169:1993;1226-1232.
50. Rosano G.M.C., Peters N.S., Lefroy D., Lindsay D., Sarrel P.M., Collins P.et al. 17β estradiol lessens angina in post-menopausal women with syndrome X. J. Am. Coll. Cardiol. 28:1996;1500-1505.
51. Rosano G.M.C., Sarrel P.M., Poole-Wilson P.A., Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet. 342:1993;133-136.
52. Rosano G.M.C., Webb C.M., Chierchia S., Morgani G.L., Gabriele M., Sarrel P.M.et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in post-menopausal women. J. Am. Coll. Cardiol. 36(7):2000;2154-2159.
53. Cerquetani E., Leonardo F., Pagnotta P., Galetta P., Onorati D., Fini M.et al. Anti-ischemic effect of chronic estrogen replacement therapy alone or in combination with medroxyprogesterone acetate in different replacement schemes. Maturitas. 39(3):2001;245-251.
54. Nachtigall L.E., Nachtigall R.H., Nachtigal R.D., Beckman E.M. Estrogen replacement therapy. II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet. Gynecol. 54:1979;74-79.
55. Falkeborn M., Persson I., Adami H.O.et al. The risk of acute myocardial infarction after estrogen and estrogen-progestogen replacement. Br. J. Obstet. Gynecol. 99:1992;821-828.
56. Psaty B.M., Heckberr S.R., Atkins D. The risk of myocardial infarction associated with the combined use of estrogens and progestins in post-menopausal women. Arch. Int. Med. 154:1994;1333-1339.
57. Gambacciani M., Rosano G.M.C., Monteleone P., Fini M., Genazzani A.R. Clinical relevance of HERS trial. Lancet. 360:2002;641.